Chemical Name: N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]urea
Biological ActivityKi 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). Does not inhibit Flt3, EGFR or c-Src. Suppresses osteoclast differentiation and osteolysis in a rat bone metastasis model.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis.
Kubota et al.
The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model.
Ohno et al.
A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno et al.
Mol.Cancer Ther., 2006;5:2634
Citation for Ki 20227
The citations listed below are publications that use Tocris products. Selected citations for Ki 20227 include:
1 Citation: Showing 1 - 1
Macrophages form functional vascular mimicry channels in vivo.
Authors: Barnett Et al.
Sci Rep 2016;6:36659
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
VersaClone cDNA Plasmids
Reviews for Ki 20227
There are currently no reviews for this product. Be the first to review Ki 20227 and earn rewards!
Have you used Ki 20227?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image